READ: ARW ON RNA

  1. Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026 12/16/2025

    Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond. 

  2. Beyond The Boom: Market Trends That Defined mRNA In 2025 12/11/2025

    Here, in part one of this multi-part series, we start by examining several of the overall market trends that took shape in 2025. In particular, we hear from Melissa Bonner, CSO of nChroma Bio, Allan Shaw, CFO of CREATE Medicines (formerly Myeloid Therapeutics), and Andy Geall, CDO of Replicate Biosciences, each of whom called out several defining characteristics that set the stage for the important work we have before us in 2026.

  3. Striking The Right Balance: The Critical Discussions Driving The mRNA Industry's Next Chapter 11/25/2025

    Now, I cannot claim that I or any of the panelists at CASSS have or had access to a real crystal ball that will show us the future. However, what did come through these discussions loud and clear is that the future of our industry must include “balance.” Here, I’ll unpack a few ways the theme of “balance” presented itself — and no doubt will continue to present itself in the future — as well as how the panelists see us achieving this necessary balance. 

  4. Trends In Oligo Scale-Up & Delivery & How They're Impacting Manufacturing 11/14/2025

    Here, a panel of experts at the RNA Leaders Conference gives a fantastic overview of where we are today and why, as one expert so nicely put it, “This is one of the most fun times to be an oligo scientist or chemist.” 

  5. Beyond the Hype: Industry Experts on the Reality of mRNA in Cancer Care 10/31/2025

    When I asked a panel of experts at RNA Leaders why mRNA was best positioned to shine in oncology, I was met with a few expected talking points and — better yet — a few I wasn’t expecting. 

  6. From Misinformation To Medicine: Forging Bipartisan Support to Reverse Anti-mRNA Policy 10/9/2025

    In this article, I’ll share some of the progress AMM has made and the barriers the organization/our industry is still facing in our efforts to reverse the policy decisions that have been made against mRNA today. Throughout the panel, the speakers also shared their thoughts on the types of messaging we should be considering and/or have started to see making an impact. 

  7. Reclaiming mRNA's Story: How U.S. Policy Upheavals Are Pushing Us To Adapt 10/2/2025

    I’d like to believe everyone reading Advancing RNA already knows that mRNA is the greatest. So, this article isn’t going to outline why the U.S. government’s current efforts to disparage mRNA are harmful. Rather, I’d like to focus on how these policies are impacting our industry in both positive and negative ways — starting with a few takeaways I gleaned from a discussion at RNA Leaders. 

  8. The Case for Process Simplification in mRNA Manufacturing 9/2/2025

    Here, I wanted to share a few additional details from Parrella’s presentation about the efforts he and his team at Kernal Biologics made to improve their overall mRNA-LNP COGS. Though he emphasized the amount of opportunity that exists to improve our utilization of costly raw materials/reagents, as he revealed, there are also opportunities for process simplification.

  9. The Price Is… Almost Right: mRNA Edition! COGS Reduction Strategies 8/28/2025

    The following article will outline the current state of COGS in the mRNA industry and the work he and his colleagues undertook to more effectively utilize raw materials. But heaven forbid this be your normal conference panel write-up. No, below I share Parrella’s insights, but in the form of a never-before released episode of The Price is Right…or perhaps more fittingly given the state of the industry today, this spectacle is more aptly titled: The Price is…Sort Of, Almost, Not Quite Right! 

  10. Translating An Early-Stage mRNA Therapeutic Into The Clinic 8/26/2025

    In the following Q&A, Ethris CMO Thomas Langenickel shares some of his biggest questions and observations about the evolving mRNA therapeutics space that are the most impactful in translating early-stage RNA candidates into the clinic — particularly when that drug product boasts a novel formulation.